TRAVELING THE WORLD, WRITING WHAT THE PEOPLE NEED TO KNOW.
TRAVELING THE WORLD, WRITING WHAT THE PEOPLE NEED TO KNOW.
Everyone – except Jeff Sessions, it seems – knows that the War on Drugs has been a failure of massive proportions, but the Attorney General is escalating it anyway. This week, Sessions ordered federal prosecutors to seek the maximum punishment for drug offenses, reversing policy made under former president Barack Obama that was designed to reduce Read More…
One-third of FDA-approved drugs were later found to have safety risks, according to a recent analysis of drugs cleared by the agency between 2001 and 2010. According to the study, published in the Journal of the American Medical Association, “Among 222 novel therapeutics approved by the FDA from 2001 through 2010, 71 (32.0%) were affected Read More…
Marijuana wasn’t always a taboo. Before 1937, when the Marihuana Tax Act of 1937 came about, which made cannabis federally illegal, pot was just about legal vice. It was smoked at jazz concerts or just after work. Some people would come home to a nice glass of wine while others came home to a joint. Well Read More…
Podcast: Play in new window | Download | EmbedSubscribe: Apple Podcasts | Email | RSSIt should not be too hard to see, especially considering the recent declaration of war by the US government, that the current path of the Trump administration is a far cry from what was promised along the campaign trail, arguably off Read More…
As Attorney General Jeff Sessions continues to lament what he views as a blight on society, a new study is showing that states with medical marijuana programs are seeing drastic reductions in opioid-related hospitalizations and overdoses. From a Reuters article published Tuesday: “In states that legalized medical marijuana, U.S. hospitals failed to see a predicted influx Read More…
After it waged a veritable war against cannabis legalization in Arizona, coughing up half a million dollars for the campaign, Insys Therapeutics recently announced the ultimate victory has finally come to fruition: the DEA approved one of the company’s groundbreaking pharmaceuticals — synthetic marijuana — to be listed as a Schedule II substance. “Insys gave $500,000 last Read More…